Trial reportWorld journal of gastroenterology2007
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.
Trial report in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00495846 (Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues: a Pilot Prospective Study Based on Somatostatin Receptors Tumors Expression
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Pooled it
- Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.Medical science monitor : international medical journal of experimental and clinical research · 2011Pooled it
- Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.Journal of cancer research and clinical oncology · 2009Pooled it
- Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.Investigational new drugs · 2015Trial
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.Biomedicines · 2024Review
- Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023Review
- Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma.Analytical cellular pathology (Amsterdam) · 2021Review
- Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.Molecules (Basel, Switzerland) · 2020Review
- Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.International journal of molecular sciences · 2019Review
- Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.Journal of hepatocellular carcinoma · 2018Article
- Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.BMC cancer · 2017Article
- Value of quality of life analysis in liver cancer: A clinician's perspective.World journal of hepatology · 2017Review
- Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.Journal of hepatocellular carcinoma · 2017Review
- Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.Oncotarget · 2016Article
- Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.World journal of gastrointestinal oncology · 2016Review
- Quality of life and hepatocellular carcinoma.Journal of gastrointestinal oncology · 2014Review
- Systemic therapy of hepatocellular carcinoma: current status and future perspectives.World journal of gastroenterology · 2014Review
- The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Infectious agents and cancer · 2014Review
- Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Frontiers in endocrinology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo estimate if and to what extent long acting octreotide (LAR) improves survival and quality of life in patients with advanced hepatocellular carcinoma (HCC).
methodsA total of 127 cirrhotics, stages A-B, due to chronic viral infections and with advanced HCC, were enrolled in the study. Scintigraphy with 111Indium labeled octreotide was performed in all cases. The patients with increased accumulation of radionuclear compound were randomized to receive either oral placebo only or octreotide/octreotide LAR only as follows: octreotide 0.5 mg s.c. every 8 h for 6 wk, at the end of wk 4-8 octreotide LAR 20 mg i.m. and at the end of wk 12 and every 4 wk octreotide LAR 30 mg i.m.. Follow-up was worked out monthly as well as the estimation of quality of life (QLQ-C30 questionnaire). Patients with negative somatostatin receptors (SSTR) detection were followed up in the same manner.
resultsScintigraphy demonstrated SSTR in 61 patients. Thirty were randomized to receive only placebo and 31 only octreotide. A significantly higher survival time was observed for the octreotide group (49+/-6 wk) as compared to the control group (28+/-1 wk) and to the SSTR negative group (28+/-2 wk), LR=20.39, df=2, P<0.01. The octreotide group presented 68.5% lower hazard ratio [95% CI (47.4%-81.2%)]. During the first year, a 22%, 39% and 43% decrease in the QLQ-C30 score was observed in each group, respectively.
conclusionThe proposed therapeutic approach has shown to improve the survival and quality of life in SSTR positive patients with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.